{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:20:56Z","timestamp":1790662856879,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,7,7]],"date-time":"2005-07-07T00:00:00Z","timestamp":1120694400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1007\/s00296-005-0004-4","type":"journal-article","created":{"date-parts":[[2005,7,6]],"date-time":"2005-07-06T22:07:36Z","timestamp":1120687656000},"page":"427-431","source":"Crossref","is-referenced-by-count":130,"title":["Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study"],"prefix":"10.1007","volume":"26","author":[{"given":"J. D.","family":"Ringe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Farahmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,7,7]]},"reference":[{"issue":"2A","key":"4_CR1","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/S0002-9343(05)80037-3","volume":"98","author":"E Barrett-Connor","year":"1995","unstructured":"Barrett-Connor E (1995) The economic and human costs of osteoporotic fracture. Am J Med 98(2A):3S\u20138S","journal-title":"Am J Med"},{"issue":"7","key":"4_CR2","first-page":"1521","volume":"67","author":"JM Campion","year":"2003","unstructured":"Campion JM, Maricic MJ (2003) Osteoporosis in men. Am Fam Physician 67(7):1521\u20131526","journal-title":"Am Fam Physician"},{"issue":"9156","key":"4_CR3","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","volume":"353","author":"JR Center","year":"1999","unstructured":"Center JR et al (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353(9156):878\u2013882","journal-title":"Lancet"},{"issue":"1","key":"4_CR4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0149-2918(04)90002-1","volume":"26","author":"WP Olszynski","year":"2004","unstructured":"Olszynski WP et al (2004) Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther 26(1):15\u201328","journal-title":"Clin Ther"},{"issue":"19","key":"4_CR5","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/archinte.162.19.2217","volume":"162","author":"GM Kiebzak","year":"2002","unstructured":"Kiebzak GM et al (2002) Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 162(19):2217\u20132222","journal-title":"Arch Intern Med"},{"issue":"5 Suppl","key":"4_CR6","first-page":"S18","volume":"180","author":"TV Nguyen","year":"2004","unstructured":"Nguyen TV, Center JR, Eisman JA (2004) Osteoporosis: underrated, underdiagnosed and undertreated. Med J Aust 180(5 Suppl):S18\u2013S22","journal-title":"Med J Aust"},{"issue":"8","key":"4_CR7","first-page":"2670","volume":"85","author":"PJ Snyder","year":"2000","unstructured":"Snyder PJ et al (2000) Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85(8):2670\u20132677","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"4_CR8","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","volume":"343","author":"E Orwoll","year":"2000","unstructured":"Orwoll E et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343(9):604\u2013610","journal-title":"N Engl J Med"},{"key":"4_CR9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s001980200013","volume":"13","author":"JD Ringe","year":"2002","unstructured":"Ringe JD, Orwoll E, Daifotis A, Lombardi A (2002) Treatment of male osteoporosis: recent advances with alendronate. Osteoporos Int 13:195\u2013199","journal-title":"Osteoporos Int"},{"key":"4_CR10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00296-003-0388-y","volume":"24","author":"JD Ringe","year":"2004","unstructured":"Ringe JD, Dorst A, Faber H, Ibach K (2004) Alendonate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 24:110\u2013113","journal-title":"Rheumatol Int"},{"key":"4_CR11","unstructured":"Physicians\u2019 desk reference: PDR (2003) 57th edn. Thomson PDR, Montvale, p 3550"},{"issue":"4","key":"4_CR12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1185\/030079903125003125","volume":"20","author":"C Roux","year":"2004","unstructured":"Roux C et al (2004) Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20(4):433\u2013439","journal-title":"Curr Med Res Opin"},{"key":"4_CR13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00223-003-0042-4","volume":"74","author":"T Harrington","year":"2004","unstructured":"Harrington T et al (2004) Risedronate rapidly reduces the risk for non-vertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129\u2013135","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"4_CR14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR et al (2001) Effect of risedronate on the risk of hip fracture in elderly women Hip Intervention Program Study Group. N Engl J Med 344(5):333\u2013340","journal-title":"N Engl J Med"},{"issue":"4","key":"4_CR15","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00223-001-1060-8","volume":"69","author":"DM Reid","year":"2001","unstructured":"Reid DM et al (2001) Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69(4):242\u2013247","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"4_CR16","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","volume":"285","author":"R Lindsay","year":"2001","unstructured":"Lindsay R et al (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285(3):320\u2013323","journal-title":"JAMA"},{"key":"4_CR17","unstructured":"Ringe JD (2000) Osteoporosis in men. In: Hosking D, Ringe J (eds) Treatment of metabolic bone disease. Management strategy and drug therapy. Martin Dunitz, London"},{"issue":"1","key":"4_CR18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00198-002-1316-9","volume":"4","author":"R Hasserius","year":"2003","unstructured":"Hasserius R et al (2003) Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int 4(1):61\u201368","journal-title":"Osteoporos Int"},{"issue":"11","key":"4_CR19","doi-asserted-by":"crossref","first-page":"919","DOI":"10.7326\/0003-4819-114-11-919","volume":"114","author":"PD Ross","year":"1991","unstructured":"Ross PD et al (1991) Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 114(11):919\u2013923","journal-title":"Ann Intern Med"},{"issue":"14","key":"4_CR20","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344\u20131352","journal-title":"JAMA"},{"issue":"1","key":"4_CR21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11(1):83\u201391","journal-title":"Osteoporos Int"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-005-0004-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-005-0004-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-005-0004-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T11:15:18Z","timestamp":1559042118000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-005-0004-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,7]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["4"],"URL":"https:\/\/doi.org\/10.1007\/s00296-005-0004-4","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,7]]}}}